1. Introduction {#sec1}
===============

Data of the use of stem cells in various diseases are accumulating. Some studies reported beneficial effects of stem cell therapy in degenerative diseases such as myocardial infarction and revealed that stem cells cause tissue repair due to their ability to secrete trophic factors that exert beneficial impact on the damaged tissue, rather than their capacity to differentiate into the needed cells \[[@B1]\]. Various studies on stem cell-derived secreted factors showed that the secreted factor alone without the stem cell itself may cause tissue repair in various conditions that involved tissue/organ damage. The secreted factors are referred to as secretome, microvesicles, or exosome and can be found in the medium where the stem cells are cultured; thus, the medium is called conditioned medium (CM) \[[@B2]\].

The use of secretome containing CM has several advantages compared to the use of stem cells, as CM can be manufactured, freeze-dried, packaged, and transported more easily. Moreover, as it is devoid of cells; there is no need to match the donor and the recipient to avoid rejection problems. Therefore, stem cell-derived conditioned medium have a promising prospect to be produced as pharmaceuticals for regenerative medicine.

To date, no clinical trial that used CM for a certain disease has been reported, except two pilot studies on the use of adipose derived mesenchymal stem cell CM for hair follicle regeneration \[[@B3]\] and fractional carbon dioxide resurfacing wound healing \[[@B4]\] in human, which showed good results. The use of CM for therapy is very appealing and may be booming in the near future, as studies on the use of CM for various diseases are accumulating \[[@B1], [@B3]--[@B34]\]. Conditioned medium contains various growth factors and tissue regenerative agents, which were secreted by the stem cells. The fact that stem cells secrete various growth factors was also shown by various proteomic studies, which revealed the presence of various growth factors and other cytokines in the CM \[[@B5], [@B7]--[@B9], [@B13], [@B18], [@B21], [@B23], [@B29], [@B35], [@B36]\].

However, various studies reported the use of various kinds of stem cells and various methods to get the CM to cure various kinds of degenerative diseases in various animal models. Therefore, this systematic review aimed to investigate the various methods to get the CM and the various diseases that were treated, to get an insight into the various kinds of CM and their application benefit in various diseases.

2. Materials and Methods {#sec2}
========================

We performed "all text" searches without time restriction on January 23, 2014, in Pubmed/Medline using keywords "stem cell" and "conditioned medium" or "secretome" and "therapy," "all text" searches in Cochrane library (trials) using keywords "secretome" or "conditioned medium," and "all text" searches in [ClinicalTrials.gov](http://clinicaltrials.gov/) using keywords "stem cell" and "conditioned medium" or "secretome" and "therapy." In addition, relevant existing articles in our library were added.

Inclusion criteria are all studies that used CM for a certain disease. Exclusion criteria are studies that did not contain complete data concerning subject condition/disease model, source of CM, and outcome of treatment with CM.

Data collection is as follows: treated conditions/diseases, type of cell that was cultured, detailed composition of medium and supplements that was used to culture the cells, culture condition (hypoxia or normoxia) to get the CM, CM processing, growth factors, and other secretions that were analyzed; method (mode) of application and outcome of CM application were noted, grouped, and tabulated.

Data synthesis is as follows: data were grouped according to treated disease and cell types that were used to produce the CM. Further, to know the growth factor yields of the various types of cells, when available, growth factor levels were tabulated and grouped according to types of cells that yielded the growth factor containing conditioned medium, in relation to the number of cells, type and duration of culture, and processing of the conditioned medium. When the data was available, the number of cells that were needed to produce the CM for one application was computed.

3. Results and Discussion {#sec3}
=========================

We got 39 articles that met the inclusion criteria, and 7 were excluded due to incomplete data. Various conditions/diseases were treated by various cell-derived CM and mostly showed promising results ([Table 1](#tab1){ref-type="table"}).

The various conditioned media, even when they were derived from same kind of cells, were produced by different condition, that is, from different passage, number of cells, culture medium, and culture condition ([Table 2](#tab2){ref-type="table"}). The growth factor yields of the various types of cells can be seen in [Table 3](#tab3){ref-type="table"}, and the cell number that is needed to produce CM for one application can be seen in [Table 4](#tab4){ref-type="table"}.

Various studies showed that conditioned medium have been tested in various kinds of diseases/conditions ([Table 1](#tab1){ref-type="table"}) \[[@B1], [@B3]--[@B34]\], that is, alopecia \[[@B3], [@B5]\], acute and chronic hind limb ischemia \[[@B6]--[@B9]\], acute and chronic wound healing \[[@B4], [@B10]--[@B14]\], myocardial infarct \[[@B1], [@B16]--[@B19]\], acute liver injury/failure \[[@B20]--[@B23]\], cerebral injury/ischemia/stroke \[[@B24]--[@B28]\], spinal cord injury \[[@B29]\], lung injury \[[@B33]\], and bone defect \[[@B34]\], and showed improvement of the conditions. Moreover, chronic kidney disease that was treated using human embryonic stem cell-derived mesenchymal stem cell (huESC-MSC) CM showed decreased systolic blood pressure and proteinuria and improvement in tubular and glomerular damage, renal blood flow, and glomerular filtration rate \[[@B30]\]. However, nephropathy that was treated using CM from human umbilical cord blood unrestricted somatic stem cell (huUCB-USSC) or mouse bone marrow mesenchymal stem cell (mBM-MSC) CM did not show improvement in serum urea and creatinine level, histopathological damage, and physical activity score \[[@B31]\]. Moreover, prevention of cancer using human mesenchymal stem cell line CM showed increased tumor cell proliferation and vascularization \[[@B32]\].

In the two cases of kidney disease, it can be concluded that CM from hu-ESC-MSC can improve the condition, and the needed growth factor level is presumably enough as CM processing includes a 25-time concentration step \[[@B30]\]. However, for hu-UCB-USSC or mBM-MSC-CM, lack of data concerning CM processing and growth factor level of the CM \[[@B31]\] prevent further analysis to conclude whether the failure to improve the condition is due to the lack of certain growth factor or due to the level of growth factors that was too low to give an effect.

The conditioned medium can be harvested from various kinds of cells ([Table 2](#tab2){ref-type="table"}). Moreover, there are various methods to get the conditioned medium, which may interfere with the growth factor types and levels that were harvested by the methods. Only some of the various studies using CM checked the growth factor levels ([Table 3](#tab3){ref-type="table"}) \[[@B5]--[@B10], [@B13], [@B18], [@B21], [@B23], [@B25], [@B26], [@B28], [@B29], [@B34], [@B37]\] and the same type of cells yielded different growth factor levels, when cell number, culture medium and condition, and CM processing were different \[[@B6], [@B25]\]. Moreover, growth factor measures also differed, that is, pg/mL or ng/mL \[[@B6], [@B8], [@B10], [@B13], [@B18], [@B25], [@B28], [@B29], [@B34]\], pg/*μ*g DNA \[[@B9], [@B37]\], fg/cell \[[@B26]\], spot density \[[@B5]\], and positive/negative \[[@B21]\] ([Table 3](#tab3){ref-type="table"}). The measure of pg/*μ*g DNA and fg/cell can be computed into pg or ng/mL provided the DNA content/cell and cell number is known. However, in some studies, the exact cell number that was used to produce the CM was not mentioned \[[@B7], [@B8], [@B10], [@B13], [@B29], [@B34], [@B37]\]. In addition, most studies measured different sets of growth factors and other cytokines/factors ([Table 3](#tab3){ref-type="table"}).

3.1. Culture Medium and Supplement {#sec3.1}
----------------------------------

Some studies used fetal bovine serum or other supplement containing complete medium, while other studies used serum-free media. Moreover, the basal media used were variable, for example, *α*MEM, DMEM, DMEM/F12, M199, EBM2, EGM-2, in vivo 15, or chemically defined medium, and the same type of cell might be cultured in different kind of basal medium ([Table 2](#tab2){ref-type="table"}). Culture medium in*in vitro* culture represents microenvironment in*in vivo* condition and may determine cell fate and thus cell secretion \[[@B38]\]. Therefore, the same type of cells may secrete different level of growth factors when they were cultured in different medium, as can be seen in [Table 3](#tab3){ref-type="table"} \[[@B26], [@B28]\].

3.2. Culture Duration {#sec3.2}
---------------------

Production of CM varies in culture duration from sixteen hours to five days ([Table 3](#tab3){ref-type="table"}). In case complete medium was used, short culture duration might leave certain serum derived growth factors that was not consumed by the cells and might add to the growth factor level, or, on the contrary, suppress growth factor secretion by the cells. Possibility of the presence of residual growth factor from the medium can be seen in a study, which showed that medium without cell contained a TGF-b1 level of 2.49 ± 2.39 pg/mL ([Table 3](#tab3){ref-type="table"}) \[[@B25]\].

3.3. Culture Condition {#sec3.3}
----------------------

Some studies produce CM from cell culture in normoxia (O~2~ level 20-21%) and variable oxygen deprived (hypoxia O~2~ level 0.5%, 1%, 1.5%, and 2%) condition ([Table 2](#tab2){ref-type="table"}). Some studies on various stem cells showed that most growth factors were upregulated in hypoxia condition, for example, vascular endothelial derived growth factor (VEGF) \[[@B5], [@B8], [@B28]\], hepatocyte growth factor (HGF) \[[@B8], [@B28]\], platelet derived growth factor (PDGF) \[[@B5], [@B8]\], placenta growth factor (PlGF) \[[@B26]\], and insulin-like growth factor II (IGF-II) \[[@B5]\], except epidermal growth factor (EGF) that was downregulated \[[@B5]\]. However, another study showed the contrary, that is, down regulation of VEGF and HGF in hypoxia condition \[[@B26]\].

Most studies produced CM in monolayer culture, but several studies used spheroid cultures ([Table 3](#tab3){ref-type="table"}). Spheroid cultures need a special handling and equipment (spinner flask) but yield more cells compared to conventional monolayer cultures, and thus more secreted factors \[[@B6], [@B25]\] ([Table 4](#tab4){ref-type="table"}). In addition, cells located at the center of the spheroid may be in relative hypoxic condition compared to cells on the surface, thus further increasing certain growth factor yield.

3.4. Secreted Factor\'s Role in Improvement of Diseases {#sec3.4}
-------------------------------------------------------

Various cytokines were secreted by stem cells into the CM, and they played a role in the improvement of various diseases/conditions. Those cytokines can be grouped into growth factors, proinflammatory and anti-inflammatory cytokines, and other cytokines. Various studies used various methods to assess various cytokines in the conditioned CM, from the conventional ELISA assays \[[@B6], [@B10], [@B25], [@B26], [@B28], [@B34], [@B37]\] to proteomic profiling methods \[[@B5], [@B7]--[@B9], [@B13], [@B18], [@B21], [@B23], [@B29], [@B35], [@B36]\].

### 3.4.1. Growth Factors {#sec3.4.1}

Growth factors that are secreted by various kinds of stem cells are vascular endothelial derived growth factor (VEGF) \[[@B5], [@B6], [@B8], [@B10], [@B13], [@B18], [@B25], [@B26], [@B28], [@B34], [@B37]\], platelet derived growth factor (PDGF) \[[@B5], [@B8], [@B10], [@B13], [@B25]\], epidermal growth factor (EGF) \[[@B5], [@B10], [@B13], [@B21]\], insulin-like growth factor I (IGF-I) \[[@B34], [@B37]\], insulin-like growth factor II (IGF-II) \[[@B5]\], hepatocyte growth factor (HGF) \[[@B6], [@B8], [@B21], [@B26], [@B28], [@B34]\], fibroblast growth factor 2/basic fibroblast growth factor (FGF-2/bFGF) \[[@B6], [@B7], [@B10], [@B13]\], keratinocyte growth factor/fibroblast growth factor 7 (KGF/FGF-7) \[[@B10], [@B21]\], platelet derived endothelial cell growth factor (PDEGF) \[[@B21]\], heparin binding epidermal growth factor (HEGF) \[[@B21]\], placenta growth factor (PlGF) \[[@B26]\], neural growth factor (NGF) \[[@B29]\], and brain derived neurotrophic factor (BDNF) \[[@B29]\].

Further, studies that analyzed various growth factors reported the presence of the various growth factors, which were secreted by various stem cells into their conditioned medium ([Table 3](#tab3){ref-type="table"}), except for human MSC (Lonza) that did not secrete FGF-2, PDGFBB, BMP-2, and SDF-1 but secreted IGF-1, VEGF, TGF *β*1, and HGF \[[@B34]\]. Moreover, different culture condition and medium may yield different level of growth factor secretions \[[@B6]\].

### 3.4.2. Pro- and Anti-Inflammatory Cytokines {#sec3.4.2}

Anti-inflammatory cytokines that are secreted by stem cells are TGF*β*1 \[[@B9], [@B10], [@B21], [@B25], [@B34]\] and some interleukins (IL), that is, IL-6 \[[@B9], [@B13], [@B18], [@B26], [@B29]\], IL-10, IL-27, IL-17E, IL-13, IL-12p70, and IL-1 receptor antagonist (IL-1ra) \[[@B21]\], while the secreted proinflammatory cytokines are IL-8/CXCL-8 \[[@B8], [@B9], [@B13]\], IL-9 \[[@B13], [@B36]\], and IL-1b \[[@B21]\].

### 3.4.3. Other Cytokines {#sec3.4.3}

Other secreted factors are leptin \[[@B7]\], angiogenin \[[@B8]\], granulocyte colony stimulating factor (GCSF) \[[@B5], [@B10]\], granulocyte macrophage CSF (GM-CSF) \[[@B5], [@B10], [@B13]\], macrophage CSF (MCSF) \[[@B5]\], fractalkine \[[@B13]\], monocyte chemotactic protein (MCP-1) \[[@B9], [@B13], [@B18], [@B21]\], serpin E-1 \[[@B21]\], endostatin/collegen XVIII \[[@B21]\], UPA, thrombospondins 1 and 2 \[[@B21]\], tissue inhibitor of metalloproteinase-1 (TIMP-1) \[[@B21]\], IGF binding protein (IGFBP) \[[@B5], [@B21]\], stem cell-derived factor 1 (SDF-1)/CXCL-12 \[[@B6]--[@B9], [@B21], [@B26]\], adrenomedullin (ADM) \[[@B26]\], Dickkopf-1 (DKK-1) \[[@B26]\], and receptors, that is, MCSF receptor (MCSFR) \[[@B5]\] and PDGF receptor (PDGFR) \[[@B5]\].

3.5. Translation of Conditioned Medium Usage in Patients {#sec3.5}
--------------------------------------------------------

In conditioned medium, various factors may be present as a cocktail and act in concert to promote regeneration. Therefore, it is important to analyze a complete set of growth factor and cytokine levels for every kind of stem cell-derived conditioned medium and to know the culture condition, conditioned medium processing, and diseases/conditions that are responsive to a certain conditioned medium treatment. When the content of the various cytokines in a certain conditioned medium is known, the result of the conditioned medium on a certain disease/condition can be determined, and the way to translation into patients is open.

From studies that analyzed VEGF level we can conclude that most stem cells secrete VEGF. As VEGF plays a role on angiogenesis \[[@B37]\] that is important in regeneration of injured/damaged tissues/organs, various stem cell-derived conditioned media are able to cure various diseases and will have more impact on diseases with ischemia. In addition, VEGF may prevent apoptosis in hypoxic condition, thus preventing further damage \[[@B6]\].

Concerning angiogenesis, other than VEGF, other growth factors that may play a role in angiogenesis are FGF2 \[[@B7], [@B39]\], EGF \[[@B7]\], HGF \[[@B7], [@B8]\], PlGF \[[@B7]\], SDF-1 \[[@B7]\], PDGF \[[@B7], [@B39]\], TGF*β*1 \[[@B39]\], and PDEGF \[[@B40]\]. In addition, various cytokines, that is, interleukin \[[@B39]\], IL-8 \[[@B8], [@B9], [@B13]\], chemokines \[[@B39]\], monocyte chemotactic protein (MCP-1) \[[@B9], [@B13], [@B18], [@B21]\], leptin \[[@B7]\], angiogenin \[[@B8]\], and endostatin/collagen XVIII \[[@B21]\], also play a role in angiogenesis.

Moreover, FGF2 is a more potent angiogenic factor compared to VEGF, with additional effect on proliferation of fibroblasts, preadipocytes, and endothelial, epithelial, and neural stem cells, on migration of neural crest derived glial and myogenic cells and on differentiation of neuroepithelial cells into mature neurons and glial cells \[[@B39]\].

Other growth factors contribute in the regeneration of injured/damaged tissue organs, with special emphasis on proliferation, that is, PDGF for connective tissue, glial, and other cells, EGF for mesenchymal, glial, and epithelial cells, and IGF-I and IGF-II for various kinds of cells \[[@B41]\]. In addition, PlGF that is a member of VEGF family increases the activity of VEGF*in vitro* and*in vivo* \[[@B42]\], KGF inhibits oxidative stress induced epithelial cell death \[[@B43]\], NGF promotes neurite outgrowth and neural cell survival \[[@B41]\], BDNF is neuroprotective, promotes cell survival, and reduces astroglial scar formation \[[@B29]\], and some growth factors, including HEGF, FGF-7, EGF, and HGF promote liver regeneration \[[@B21]\].

Proinflammatory cytokines that play a role in regeneration are IL-1b due to its liver protective role \[[@B21]\], IL-8 due to its angiogenic activity \[[@B8], [@B9], [@B13]\], and IL-9 due to wound healing promotion activity \[[@B13], [@B44]\]. In addition, anti-inflammatory cytokines prevent inflammation and promote liver regeneration \[[@B21]\].

Other cytokines, that is, UPA and thrombospondins 1 and 2, promote liver regeneration \[[@B21]\], serpin E-1 \[[@B21]\] and SDF-1 \[[@B6]--[@B9], [@B21], [@B26]\] promote tissue repair \[[@B21]\], TIMP-1 and IGFBP \[[@B5], [@B21]\] prevent apoptosis \[[@B21]\], ADM causes vasodilatation and reduces cellular oxidative stress and apoptosis \[[@B26]\], DKK-1 initiates bone marrow stem cell proliferation \[[@B26]\], and fractalkine prevents apoptosis \[[@B13], [@B45]\].

Various colony stimulating factors, that is, granulocyte colony stimulating factor (GCSF) \[[@B5], [@B10]\], granulocyte macrophage CSF (GM-CSF) \[[@B5], [@B10], [@B13]\], and macrophage CSF (MCSF) \[[@B5]\], may recruit various resident stem cells/progenitor cells including endothelial progenitors to site of injury/damage and promote wound healing process \[[@B10], [@B13]\] or hair growth \[[@B5]\].

MCSF receptor (MCSFR) \[[@B5]\] promotes myeloid progenitor, mononuclear phagocyte, and placental trophoblast growth and development \[[@B46]\], and PDGFR \[[@B5]\] may interact with various signaling molecules or integrin to cause cell proliferation, motility, differentiation, or survival by apoptosis inhibition \[[@B47]\].

Moreover, one factor may contribute to more than one mode of regenerative action, such as MCP-1 that is involved in angiogenesis \[[@B9], [@B13], [@B18], [@B21]\] and liver protection activity \[[@B21]\]. Further, for production of CM to be applied in various human diseases, data from animal studies that showed promising outcome are very valuable.

### 3.5.1. Production of CM for Translation into Various Human Diseases {#sec3.5.1}

To use CM for various human diseases, production method of the CM needs to be standardized in terms of the type and number of cells that were needed to produce the CM, culture medium and condition, and conditioned medium processing. In addition, the volume and mode of delivery are also important. As various studies used various numbers and type of cells and various doses of CM, it is important to know the number of cells that yielded the CM for one application, which may be interpolated for human studies. Therefore, in [Table 4](#tab4){ref-type="table"} we summarized all data that may be needed for interpolation into human studies, that is, diseases that were treated, species and age or body weight of the animal, type of cell, culture medium and condition, number of cells to produce CM for one application, volume, and mode of application. Moreover, various possible applications of CM for various conditions are summarized in [Figure 1](#fig1){ref-type="fig"}.

In addition, for translation into patients, it is very important to analyze and to note the various cytokine contents of the various conditioned media. Further, for every conditioned medium with known cytokine content, validation of its use on various diseases needs to be conducted. Finally, the possibility of promotion of existing cancer should be tested for every CM, and caution should be taken before CM therapy to ensure that the recipient is free from cancer.

Advantages of production of various CM for patients lie in the possibility of mass production by pharmaceutical companies, when production methods have been standardized. Conditioned media are not like stem cells that need a good manufacturing practice (GMP) facility to be applied to patients \[[@B48]\]. When CM has been packaged properly, it can be transported easily as drugs and does not need cryopreservation, such as that the stem cells need. However, compared to stem cells that may survive for a rather long period, CM needs to be given more frequently, as cytokines\' and growth factors\' half-lives are mostly shorter \[[@B49], [@B50]\], which is a disadvantage for the patients but will give more profit to pharmaceutical companies.

4. Conclusion {#sec4}
=============

Various stem cell-derived conditioned media were produced by various methods and processing and tested on various diseases and mostly showed good results. However, standardized methods for various conditioned media production and validations of their use on various diseases need to be conducted.
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![Various possible applications of CM for various conditions.](BMRI2014-965849.001){#fig1}

###### 

Studies on various subjects, conditions, source of conditioned medium, and outcome.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition/disease                                                                                Subject                       Source of conditioned medium                                                                                      Outcome                                                                                                         Reference number
  ------------------------------------------------------------------------------------------------ ----------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------
  Alopecia---ID                                                                                    Human                         Hu-AD-MSC                                                                                                         Increased hair growth                                                                                           \[[@B3]\]

                                                                                                                                                                                                                                                                                                                                                                   

  Bald---SC                                                                                        C~3~H/HeN nude mice           Hu-AD-SC                                                                                                          Hair growth                                                                                                     \[[@B5]\]

                                                                                                                                                                                                                                                                                                                                                                   

  Acute hind limb ischemia---direct IM                                                             Female athymic mouse          Hu-AD-SC                                                                                                          Decreased LL and F\                                                                                             \[[@B6]\]
                                                                                                                                                                                                                                                   Increased BF, angiogenesis, endothelial growth, homing, and AA                                                  

  SCID mice                                                                                        Hu-ESC---endothelial cells    Vascularization and BF: CM restored defective diabetic PB derived PAC                                             \[[@B7]\]                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                   

  Chronic hind limb ischemia---7--10 days IM                                                       Male nude athymic             Hu-PB-MNC-EPC\                                                                                                    Increased hind limb BF                                                                                          \[[@B8]\]
                                                                                                                                 Hu-UC-HUVEC                                                                                                                                                                                                                       

  Male NOD-SCID mouse                                                                              Hu-AF---SC---Ckit (+)         Increased arteriogenesis, capillary density, total perfusion area, and mobility, and decreased muscular deg       \[[@B9]\]                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                   

  Skin wound direct---ID, \[[@B11]\] SC \[[@B10], [@B12]\]/topical application \[[@B4], [@B13]\]   Human                         Hu-AD-SC                                                                                                          Enhanced wound healing\                                                                                         \[[@B4]\]
                                                                                                                                                                                                                                                   Reduced adverse effects                                                                                         

  BALBc nude mice                                                                                  \(i\) Hu-UCB-MNC ⟶ UCB-SC\    Faster wound healing:\                                                                                            \[[@B10]\]                                                                                                      
                                                                                                   (endothelial + MSC)\          UCB-SC was better than HUVEC                                                                                                                                                                                                      
                                                                                                   (ii) HUVEC                                                                                                                                                                                                                                                      

  Diabetic immunodeficient mice                                                                    Hu-UCB-CD34-EPC               Faster wound closure\                                                                                             \[[@B11]\]                                                                                                      
                                                                                                                                 Less granulation tissue area\                                                                                                                                                                                                     
                                                                                                                                 More neovascularization                                                                                                                                                                                                           

  Male db/db (diabetic) mice                                                                       Hu-UC-MSC                     Faster wound closure\                                                                                             \[[@B12]\]                                                                                                      
                                                                                                                                 Increased capillary density                                                                                                                                                                                                       

  BALBc-nude mouse                                                                                 \(i\) Hu-ESC---derived EPC\   Faster wound healing, granulation, and reepithelization: huESC-EPC was better than UCB-EPC                        \[[@B13]\]                                                                                                      
                                                                                                   (ii) Hu-UCB-EPC                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                   

  Skin wound---48 hour after wound---SC                                                            Male NOD-SCID mice            Hu-BM-MSC                                                                                                         Faster wound healing                                                                                            \[[@B14]\]

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---direct---peri-infarct injection                                                            Male SCID or C57BL/6 mouse    Hu-AD-SC                                                                                                          Improved cardiac function\                                                                                      \[[@B1]\]
                                                                                                                                                                                                                                                   Reduced infarct size\                                                                                           
                                                                                                                                                                                                                                                   Effect of huAD-SC \> CM                                                                                         

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---end of 2nd hour R---IC                                                                     Female L pig                  Porcine PB-EPC                                                                                                    Reduced IZ-A and infarct size\                                                                                  \[[@B16]\]
                                                                                                                                                                                                                                                   Increased IZ angiogenesis\                                                                                      
                                                                                                                                                                                                                                                   IZ cardiomyocyte hypertrophy\                                                                                   
                                                                                                                                                                                                                                                   Improved LV contractility and\                                                                                  
                                                                                                                                                                                                                                                   relaxation                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---4 hours---IV (jugular vein)                                                                DL pig                        Hu-ESC-MSC                                                                                                        Increased capillary density\                                                                                    \[[@B17]\]
                                                                                                                                                                                                                                                   Reduced infarct size\                                                                                           
                                                                                                                                                                                                                                                   Preserved S-D performance                                                                                       

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---48 hours-IM yo                                                                             Rat nude athymic              Hu-BM-derived MPC                                                                                                 Improved LV function\                                                                                           \[[@B18]\]
                                                                                                                                                                                                                                                   Reduced LV dilation, myocyte A, and fibrosis\                                                                   
                                                                                                                                                                                                                                                   Increased neovascularization                                                                                    

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---5 min before R---IV, -at R---IC                                                            Female DL pig                 Hu-ESC derived MSC                                                                                                \(i\) Reduced infarct size and A\                                                                               \[[@B19]\]
                                                                                                                                                                                                                                                   (ii) Improved S-D performance                                                                                   

                                                                                                                                                                                                                                                                                                                                                                   

  MCI---5 min before R---IV---(tail)                                                               Mouse                         Hu-ESC derived MSC                                                                                                Reduced infarct size\                                                                                            
                                                                                                                                                                                                                                                   (\>1000 kD/100--220 nm) = 10--220 nm \< 10--100 nm                                                              

                                                                                                                                                                                                                                                                                                                                                                   

  RSLT---direct---IV---(penile)                                                                    Male SD rat                   Rat BM-MSC                                                                                                        Reduced LIB and PIC\                                                                                            \[[@B20]\]
                                                                                                                                                                                                                                                   Increased survival                                                                                              

                                                                                                                                                                                                                                                                                                                                                                   

  Acute hepatic failure---24 hours---intrahepatic (left liver lobe)                                CCl4 injured SCID/NOD mice    1-Hu-AF MSC\                                                                                                      \(i\) AST, ALT decreased\                                                                                       \[[@B21]\]
                                                                                                                                 2-AF-MSC-hepatic progenitor-like cells (HPL)                                                                      (ii) Liver phenotype improvement\                                                                               
                                                                                                                                                                                                                                                   HPL was better than MSC-CM                                                                                      

                                                                                                                                                                                                                                                                                                                                                                   

  Fulminant hepatic failure---24 hours---IV (penile)                                               Male SD rat                   Hu-MSC                                                                                                            Reduced ALT, AST, TNF*α*, IL6, and IL1-rec-A level, and HP, ICI, and A\                                         \[[@B22]\]
                                                                                                                                                                                                                                                   Increased IL10 level, liver regeneration, and survival                                                          

  Male SD rat                                                                                      Hu-BM-MSC                     Reduced panlobular leucocyte infiltrate, hepatocellular death, and bile duct duplication and increased survival   \[[@B23]\]                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                   

  Focal cerebral ischemia---72 hours---intranasal                                                  Male SD rat                   \(i\) Hu-SC-EDT\                                                                                                  Increased migration-diff---endogenous NPC, vasculogenesis, and motor function, and reduced infarct size\        \[[@B24]\]
                                                                                                                                 (ii) BM-MSC (Lonza)                                                                                               (Hu SC-EDT = BM-MSC)                                                                                            

                                                                                                                                                                                                                                                                                                                                                                   

  Ischemic stroke---after 8 days---lateral ventricle infusion                                      Male SD mice                  Hu-AD-MSC                                                                                                         Motor function maintained, reduced infarct volume, neural cell A, and astrogliosis, and increased microvessel   \[[@B25]\]

                                                                                                                                                                                                                                                                                                                                                                   

  Cerebral ischemia infarction---1 day---IC/intracardiac (LV) injection                            immunodeficient mice          \(i\) Hu-BM-MSC\                                                                                                  Reduced cortical infarct volume\                                                                                \[[@B26]\]
                                                                                                                                 (ii) Hu-BM-CD133\                                                                                                 (huBM-CD133-CM \< huBM-MSC-CM \< hufibroCM \< huBM-p75CM)                                                       
                                                                                                                                 (iii) Hu-BM-p75\                                                                                                                                                                                                                  
                                                                                                                                 (iv) Hu-fibro                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                   

  Fluid percussion-TBI---direct IV jugular vein                                                    Male SD rat                   Hu-BM-MSC                                                                                                         Reduced neuron loss, A, neuron A, infarction volume, and motor deficit\                                         \[[@B27]\]
                                                                                                                                                                                                                                                   Increased VEGF(+) cells                                                                                         

                                                                                                                                                                                                                                                                                                                                                                   

  Fluid percussion TBI---12 hours after---IV                                                       Male SD rat                   Hu-BM-MSC                                                                                                         Decreased brain damage volume, brain damage incidence, and neuron A (hypoxia \< normoxia)\                      \[[@B28]\]
                                                                                                                                                                                                                                                   Increased motor/cognitive function and neurogenesis (hypoxia \> normoxia)                                       

                                                                                                                                                                                                                                                                                                                                                                   

  Contusion spinal cord injury---direct                                                            Female Wistar rat             Rat-BM-MSC                                                                                                        Increased motor recovery                                                                                        \[[@B29]\]

                                                                                                                                                                                                                                                                                                                                                                   

  Chronic kidney disease---week 5---IV (tail)                                                      Male Le rat                   Hu embryonic MSC---stable---80 population doublings                                                               Decreased systolic BP, proteinuria, and tubular + glomerular damage\                                            \[[@B30]\]
                                                                                                                                                                                                                                                   Increased inulin and PAH clearance, glomerular endothelium, and DNA repair                                      

                                                                                                                                                                                                                                                                                                                                                                   

  Nephropathy---24 hours---IV (tail)                                                               Mouse BALBc                   \(i\) Hu-UCB-USSC\                                                                                                No improvement in serum urea and creatinine, HP, and physical activity score                                    \[[@B31]\]
                                                                                                                                 (ii) Mouse BM-MSC                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                   

  Normal---cancer cell line + CM xenograft                                                         BALB mice                     Hu-MSC (cell line)                                                                                                Increased tumor cell proliferation (PCNA) and vascularization                                                   \[[@B32]\]

                                                                                                                                                                                                                                                                                                                                                                   

  VILI---before induction---IV---(tail)                                                            Male C57BL/6 mouse            Mouse-iPSC                                                                                                        Reduced tidal volume, and bronchial microstructure restored                                                     \[[@B33]\]

                                                                                                                                                                                                                                                                                                                                                                   

  Intrabony periodontal defect direct---implant                                                    Hybrid dog                    Hu-MSC (Lonza)                                                                                                    Increased alveolar bone and cementum regeneration                                                               \[[@B34]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ID: intradermal, IM: intramuscular, SC: subcutaneous, MCI: myocardial infarct, R: reperfusion, IC: intracoronary artery, IV: intravenous, Imyo: intramyocardial, LV: left ventricular, RSLT: 50% reduced size liver transplantation, TBI: traumatic brain injury, VILI: ventilator induced lung injury, SCID: severe combined immunodeficient, NOD: nonobese diabetic, SD: Sprague-Dawley, DL: Dalland Landrace, L: Landrace, W: Wistar, Le: Lewis, hu: human, AD: adipose tissue derived, MSC: mesenchymal stem cells, SC: stem cell, ESC: embryonic stem cell, PB: peripheral blood, MNC: mononuclear cell, UC: umbilical cord, UCB: UC blood, BM: bone marrow, EPC: endothelial progenitor cell, HUVEC: human umbilical vein endothelial cell, AF: amniotic fluid, EDT: exfoliated deciduous tooth, MPC: mesenchymal progenitor cell, USSC: unrestricted somatic stem cell, iPSC: induced pluripotent stem cell, LL: limb lost, F: fibrosis, BF: blood flow, AA: antiapoptosis, CM: conditioned medium, PAC: proangiogenic cells, deg: degeneration, IZ: infarct zone, A: apoptosis, ALT: alanine amino transferase, AST: aspartate aminotransferase, HP: histopathology, ICI: immune cell infiltration, S-D: systolic-diastolic, LIB: liver injury biomarker, PIC: proinflammatory cytokine, Hu-SC-, IL1-rec-A: IL1 receptor antagonist, NPC: neural progenitor cell, PAH: para amino hippuric acid.

###### 

Cell type, medium, culture condition, cell number, duration, passage, and processing of conditioned medium.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference number     Cell type                     Medium/vessel                                                                      Culture condition              Cell number                               Duration       Passage    CM processing
  -------------------- ----------------------------- ---------------------------------------------------------------------------------- ------------------------------ ----------------------------------------- -------------- ---------- ----------------------------------------------
  \[[@B7]\]            Hu-ESC-EC\                    EBM2                                                                               NA                             NA                                        5 days         NA         NA
                       HUVEC                                                                                                                                                                                                               

  \[[@B13]\]           \(i\) Hu-ESC-CD133/KDR-EPC\   EGM-2 (Lonza)---15 mL\                                                             NA                             80%                                       48 hours       P5--8      Conc. 50x\
                       (ii) Hu-UCB-EPC               150 mm culture dish                                                                                                                                                                   10 kD

  \[[@B17]\]\          Hu-ESC-MSC\                   DMEM---insulin, transferrin, selenoprotein, FGF2, PDGF-AB, glutamine, and *β*-ME   NA\                            NA\                                       3 days\        ≥80 PD\    Conc. 25x 10 kD---220 nm → 0.5 mg/mL protein
  \[[@B30]\]           Hu-ESC-MSC                                                                                                       NA                             NA                                        3 days         80 PD      

  \[[@B19]\]           Hu-ESC-MSC                    Chemically defined medium                                                          NA                             NA                                        3 days         80 PD      Conc. 25x\
                                                                                                                                                                                                                                           10 kD^a^

  \[[@B9]\]            Hu-AF SC---Ckit (+)           *α*MEM\                                                                            5% CO~2~                       150.000\                                  16 hours       NA         from 500.000 cells---1 mL---Conc. → 80 *µ*L
                                                     Six-well plate                                                                                                    70%                                                                 

  \[[@B21]\]           1-Hu-AF-MSC\                  DMEM 0.5% FBS\                                                                     5% CO~2~                       1.5 × 10^6^ \                             24 hours       P5--13     Conc. 25x\
                       2-hu-AF-MSC-HPL               25 cm^2^ TC flask                                                                                                 80%                                                                 3 kD

  \[[@B8]\]            \(i\) Hu-PB-MNC-EPC\          EBM2 (Lonza) 1% FBS                                                                1.5% O~2~,\                    NA                                        72 hours       NA         NA
                       (ii) HUVEC                                                                                                       5% CO                                                                                              

  \[[@B16]\]           Porcine PB-MNC-EPC            Ex vivo 15 (Lonza)---VEGF 1 ng/mL---FC plate                                       5% CO~2~                       From 30--40 mL PB                         48 hours       P0         Centr. 600 g\
                                                                                                                                                                                                                                           5 min, 0.2 *μ*m---ice

  \[[@B12]\]           Hu-UC-MSC                     M199                                                                               5% CO~2~                       NA                                        24 hours       P3         Conc.-\
                                                                                                                                                                                                                                           0.2 *μ*m

  \[[@B10]\]           \(i\) Hu-UCB-MNC-SC\          EGM-2--15 mL\                                                                      5% CO~2~                       80%                                       48 hours       P5--8      Conc. 50x---10 kD
                       (endothelial + MSC)\          150 mm culture dish                                                                                                                                                                   
                       (ii) HUVEC                                                                                                                                                                                                          

  \[[@B11]\]           Hu-UCB-CD34-EPC               M199 basal medium                                                                  5% CO~2~                       1 × 10^6^                                 24 hours       NA         Conc.

  \[[@B31]\]           \(i\) Hu-UCB-USSC\            Ultra CULTURE medium 7.5% BABLc serum                                              5% CO~2~                       60%                                       48 hours       NA         NA
                       (ii) mBM-MSC                                                                                                                                                                                                        

  \[[@B14]\]           Hu-BM-MSC                     *α*MEM 10% FBS                                                                     5% CO~2~                       2 × 10^7^/flask 60--70%                   Till 60--70%   P5         Conc. 50x---5 kD\
                                                                                                                                                                                                                                           5 flask → 100 *μ*L

  \[[@B23]\]           Hu-BM-MSC                     NA-0.05% BSA                                                                       NA                             2 × 10^6^                                 24 hours       P3--7      Conc. 25x---3 kD

  \[[@B27]\]           Hu-BM-MSC                     DMEM-0.05% BSA                                                                     normoxia                       2 × 10^6^                                 24 hours       P3--7      Conc. 25x---3 kD

  \[[@B28]\]           Hu-BM-MSC                     DMEM-0.05% BSA                                                                     5% CO~2~ \                     2 × 10^6^ →\                              24 hours       P3--7      Conc. 25x\
                                                                                                                                        0.5% O~2~                      split 1 : 2 \                                                       3 kD
                                                                                                                                                                       → confl                                                             

  \[[@B18]\]           Hu-BM-MNC-stro-3-MPC          *α*MEM                                                                             NA                             1 × 10^6^ MPC                             NA             P5         Conc.

  \[[@B26]\]           \(i\) Hu-BM-MSC\              *α*MEM                                                                             5% CO~2~ \                     1 × 10^6^ \                               48 hours       P4-5       0.2 *µ*m---80°C \
                       (ii) Hu-BM-CD133\                                                                                                (i) 1% O~2~ \                  90%                                                                 conc. 40x---5 kD
                       (iii) Hu-BM-p75\                                                                                                 (ii) 21% O~2~                                                                                      
                       (iv) Hu-fibro                                                                                                                                                                                                       

  \[[@B29]\]           Rat-BM-MSC                    DMEM\                                                                              NA                             90%                                       48 hours       P2--4      Conc. 40x---10 kD: 10mL → 250 *µ*L\
                                                     T75 flask                                                                                                                                                                             0.22 *µ*m---80°C

  \[[@B20]\]           Rat BM-MSC                    DMEM-0.05% BSA\                                                                    NA                             80--90%                                   12 hours       P3-4       Conc. 25x\
                                                     10 mL                                                                                                                                                                                 3 kD

  \[[@B24]\]           \(i\) Hu-SC-EDT\              DMEM                                                                               5% CO~2~                       4 × 10^5^                                 48 hours       P3--5      3000 rpm---3 min → supernatant
                       (ii) BM-MSC (Lonza)                                                                                                                                                                                                 

  \[[@B3]\]            Hu-AD-MSC                     NA                                                                                 Hypoxia                        NA                                        NA             NA         Conc.-freeze dried

  \[[@B25]\]           Hu-AD-MSC                     *α*MEM 70 mL                                                                       Spheroid 1% O~2~---5% CO~2~    4.2 × 107                                 2 days         NA         Centr.

  \[[@B6]\]            Hu-AD-SC                      CRM/*α*MEM\                                                                        1% O~2~---5% CO~2~             2.5--3 × 10^5^/mL---24 mL---150 cm dish   2 days         Up to P5   Centr.
                                                     CRM---hu allo 10%\                                                                                                                                                                    
                                                     *α*MEM---FBS 10%                                                                                                                                                                      

  CRM/*α*MEM\          Spheroid\                     6--12 × 10^5^/mL---30 *μ*L → 70 mL flask                                                                                                                                              
  CRM---hu allo 10%\   1% O~2~---5% CO~2~                                                                                                                                                                                                  
  *α*MEM FBS 10%                                                                                                                                                                                                                           

  \[[@B1]\]            Hu-AD-SC                      NA                                                                                 NA\                            1 × 10^5^ →80%                            24 hours       NA         Centr. 300 g\
                                                                                                                                        Reference \[[@B13], [@B14]\]                                                                       5 min---220 nm

  \[[@B5]\]            Hu-AD-SC                      DMEM/F12                                                                           2% O~2~ \                      4 × 10^5^                                 72 hours       P4-5       Centr. 300 g 5\'\
                                                                                                                                        5% CO~2~                                                                                           0.22 *µ*m, 3 kD

  \[[@B24]\]           Hu-MSC                        DMEM-0.05% BSA 15 mL---175 cm^2^ flask                                             NA                             1 × 10^6^ \                               24 hours       NA         Conc. 25x 3 kD
                                                                                                                                                                       70--80%                                                             

  \[[@B32]\]           Hu-MSC (cell line)            DMEM-10% FBS\                                                                      5% CO~2~                       70%                                       48 hours       NA         100,000 g---1 hour → supernatant\
                                                     5 mL                                                                                                                                                                                  0.22 *µ*m

  \[[@B34]\]           Hu-MSC (Lonza)                DMEM                                                                               5% CO~2~                       70%                                       48 hours       P3--9      4°C or −80°C

  \[[@B33]\]           Mouse-iPSC                    NA                                                                                 NA                             NA                                        NA             NA         NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hu: human, ESC: embryonic stem cell, EC: endothelial cell, HUVEC: human umbilical vein endothelial cell, EPC: endothelial progenitor cell, AF: amniotic fluid, SC: stem cell, MSC: mesenchymal SC, HPL: hepatic progenitor-like cell, AD: adipose tissue derived, PB: peripheral blood, MNC: mononuclear cell, UC: umbilical cord, UCB: UC blood, m: mouse, BM: bone marrow, MPC: mesenchymal progenitor cell, fibro: fibroblast, EDT: exfoliated deciduous tooth, iPSC: induced pluripotent SC, TC: tissue culture, NA: not available, FBS: fetal bovine serum, allo: allogenic serum, BSA: bovine serum albumin. ∗Filtered 220 nm → 10 nm → 100 nm yielded 10--220 nm versus 10--100 nm (\<1000 kD) versus 100--220 nm (\>1000 kD). FC: fibronectin coated, P: passage, PD: population doubling, CM: conditioned medium, conc.: concentrated, centr.: centrifugation.

###### 

Growth factor level from various cell sources, culture duration, cell number and processing of conditioned medium.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference number                        Cell source                         Culture/duration       Cell number/processing                              Growth factor level                                                                        
  --------------------------------------- ----------------------------------- ---------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------
  \[[@B7]\]                               Hu-ESC-EC                           Monolayer ---5 days    NA                                                  Angiogenic cytokine: VEGF, SDF-1, PlGF, leptin, EGF, bFGF, and HGF:\                       
                                                                                                                                                         CM DM-PAC \< CM cPAC\                                                                      
                                                                                                                                                         Angiogenic cytokine: VEGF, PDGF, ICAM-1, EGF, and bFGF: CM ESC-EC \> CM c-PAC = CM D-PAC   

                                                                                                                                                                                                                                                    

  \[[@B13]\]                              \(i\) Hu-ESC-CD133/KDR-EPC\         Monolayer---48 hours   80% in 150 mm culture dish/Conc. 50x                EGF                                                                                        ESC-EPC versus CB-EPC versus EGM-2\
                                          (ii) Hu-UCB-EPC                                                                                                                                                                                           12584 versus 12654 versus 9 pg/mL

  FGF-2                                   383 versus 652 versus 61                                                                                                                                                                                  

  Fractalkine                             1605 versus 150 versus 133                                                                                                                                                                                

  GM-CSF                                  755 versus 323 versus 313                                                                                                                                                                                 

  IL-6                                    4332 versus 1961 versus 2463                                                                                                                                                                              

  IL-8                                    239030 versus 13629 versus 7                                                                                                                                                                              

  IL-9                                    345 versus 42 versus 9                                                                                                                                                                                    

  IP-10                                   458 versus 513 versus 511                                                                                                                                                                                 

  MCP-1                                   63 versus 3201 versus 1902                                                                                                                                                                                

  PDGF-AA                                 6667 versus 5568 versus 41                                                                                                                                                                                

  PDGF-AB/BB                              17 versus 1884 versus 75                                                                                                                                                                                  

  VEGF                                    4265 versus 538 versus 42                                                                                                                                                                                 

                                                                                                                                                                                                                                                    

  \[[@B9]\]                               Hu-AF SC---Ckit (+)                 Monolayer---16 hours   15 × 10^4^---70%/from 5 × 10^5^ cells Conc. 12.5x   VEGF, IL-8, SDF-1                                                                          1 ng/170.000 cell (1 *μ*g DNA)

  IL-6, MCP-1                             0.5 ng/170.000 cell                                                                                                                                                                                       

  TGF-b                                   0.2 ng/170.000 cell                                                                                                                                                                                       

  IFNg                                    ---                                                                                                                                                                                                       

  IP-10 /CXCL10                           ---                                                                                                                                                                                                       

  IL-1a                                   ---                                                                                                                                                                                                       

                                                                                                                                                                                                                                                    

  \[[@B21]\]                              \(i\) Hu-AF-MSC\                    Monolayer---24 hours   1.5 × 10^6^ \                                       Proteome analysis\                                                                         
                                          (ii) Hu-AF-MSC-HPL                                         80%/\                                               **Hu-AF-MSC-HPL-CM**:\                                                                     
                                                                                                     Conc. 25x                                           Anti-inflammatory cytokine: IL-10, IL-27, IL-17E, IL-13, IL-12p70, and IL-1ra\             
                                                                                                                                                         Liver protection: MCP- 1, IL-1b\                                                           
                                                                                                                                                         **Hu-AF-MSC-HPL-CM, AF-MSC-CM**:\                                                          
                                                                                                                                                         Anti-inflammatory cytokine: TGF*β*1\                                                       
                                                                                                                                                         Tissue repair: serpin E1, SDF-1\                                                           
                                                                                                                                                         Angiogenesis: VEGF, PDEGF, and endostatin/collagen XVIII\                                  
                                                                                                                                                         Liver regeneration: UPA, thrombospondin 1 and 2, HEGF, FGF-7, EGF, and HGF\                
                                                                                                                                                         Anti-apoptotic markers: TIMP-1, IGFBP                                                      

                                                                                                                                                                                                                                                    

  \[[@B8]\]                               \(i\) Hu-PB-MNC-\                   Monolayer---72 hours   NA                                                  IL-8/CXCL8\                                                                                29090.7 ± 12279.4 pg/mL\
                                          EPC\                                                                                                           Hypox versus norm                                                                          versus 2282.1 ± 406.3 pg/mL
                                          (ii) HUVEC                                                                                                                                                                                                

  SDF-1/CXCL12                            6059.9 ± 654.6 pg/mL\                                                                                                                                                                                     
                                          versus 3179.9 ± 488.0 pg/mL                                                                                                                                                                               

  HGF                                     539.5 ± 141.7 pg/mL\                                                                                                                                                                                      
                                          versus 343.4 ± 74.8 pg/mL                                                                                                                                                                                 

  Angiogenin                              144.6 ± 68.2 pg/mL\                                                                                                                                                                                       
                                          versus 72.5 ± 15.8 pg/mL                                                                                                                                                                                  

  PDGF-BB                                 111.6 ± 27.02 pg/mL\                                                                                                                                                                                      
                                          versus 19.9 ± 2.2 pg/mL                                                                                                                                                                                   

  VEGF-A                                  25.5 ± 4.8 pg/mL\                                                                                                                                                                                         
                                          versus 11.4 ± 5.2 pg/mL                                                                                                                                                                                   

                                                                                                                                                                                                                                                    

  \[[@B10]\]                              Hu-UCB SC (endothelial + MSC)       Monolayer---48 hours   80%/Conc. 50x                                       EGF                                                                                        3,286 ± 419 pg/mL

  VEGF                                    2,463 ± 151 pg/mL                                                                                                                                                                                         

  G-CSF                                   3,615 ± 173 pg/mL                                                                                                                                                                                         

  GM-CSF                                  3,623 ± 345 pg/mL                                                                                                                                                                                         

  TGF-*β*1, PDGF,\                        =HUVEC                                                                                                                                                                                                    
  bFGF, and KGF                                                                                                                                                                                                                                     

  HUVEC                                   Monolayer---48 hours                80%/Conc. 50x          EGF                                                 UCB-SC-4.8X                                                                                

  VEGF                                    UCB-SC-42x                                                                                                                                                                                                

  G-CSF                                   UCB-SC-3.7x                                                                                                                                                                                               

  GM-CSF                                  UCB-SC-2.4x                                                                                                                                                                                               

                                                                                                                                                                                                                                                    

  \[[@B23]\]                              Hu-BM-MSC                           Monolayer---24 hours   2 × 10^6^/Conc. 25x                                 69 from 174 prot. tested (+)\                                                              
                                                                                                                                                         (concentration NA)                                                                         

                                                                                                                                                                                                                                                    

  \[[@B28]\]                              Hu-BM-MSC                           Monolayer---24 hours   4 × 10^6^/Conc. 25x                                 VEGF\                                                                                      Normoxia: 230 pg/mL\
                                                                                                                                                          \                                                                                         Hypoxia: 450 pg/mL\
                                                                                                                                                         HGF                                                                                        Normoxia: 600 pg/mL\
                                                                                                                                                                                                                                                    Hypoxia: 750 pg/mL

                                                                                                                                                                                                                                                    

  \[[@B18]\]                              Hu-BM-MNC-stro-3-MPC                NA                     1 × 10^6^/Conc.                                     IL-6 = 2x C                                                                                118.04 ± 0.27 pg/mL

  MCP-1 = 2x C                            521.89 ± 1.48 pg/mL                                                                                                                                                                                       

  VEGF = 2x C                             33.95 ± 2.98 pg/mL                                                                                                                                                                                        

                                                                                                                                                                                                                                                    

  \[[@B26]\]                              \(i\) Hu-BM-MSC\                    Monolayer---48 hours   1 × 10^6^ \                                         Secretion/cell                                                                             P75 versus CD133 versus BMMSC
                                          (ii) Hu-BM-CD133\                                          90%/\                                                                                                                                          
                                          (iii) Hu-BM-p75                                            Conc. 40x                                                                                                                                      

  IL6---norm                              3.8 versus 0.8 versus 0.6 fg                                                                                                                                                                              

  IL6---hypox                             0.25 = 0.25 versus 0.1 fg                                                                                                                                                                                 

  PlGF---norm                             0.045 versus 0.01 versus 0 fg                                                                                                                                                                             

  PlGF---hypox                            0.043 versus 0.025 versus 0.15 fg                                                                                                                                                                         

  ADM---norm                              0.1 versus 0.05 versus 0.2 fg                                                                                                                                                                             

  ADM---hypox                             5.8 versus 5.4 versus 11.5 fg                                                                                                                                                                             

  VEGF---norm                             1.5 versus 1.0 versus 1.35 fg                                                                                                                                                                             

  VEGF---hypox                            0.7 versus 0.9 versus 0.95 fg                                                                                                                                                                             

  SDF-1---norm                            1.35 versus 0.75 versus 0.15 fg                                                                                                                                                                           

  SDF-1---hypox                           0.4 versus 0.7 versus 1.0 fg                                                                                                                                                                              

  HGF---norm                              0.84 versus 0.7 versus 0.25 fg                                                                                                                                                                            

  HGF---hypox                             0.01 versus 0.25 versus 0.01 fg                                                                                                                                                                           

  DKK-I---norm                            4 versus 4 versus 4.5 fg                                                                                                                                                                                  

  DKK-1---hypox                           6.8 versus 6.5 versus 10.5 fg                                                                                                                                                                             

                                                                                                                                                                                                                                                    

  \[[@B29]\]                              Rat-BM-MSC                          Monolayer---48 hours   90%\                                                23 from 90 prot. tested (+)                                                                
                                                                                                     T75/Conc. 40x                                                                                                                                  

  NGF                                     356 ± 117 pg/mL                                                                                                                                                                                           

  BDNF                                    208 ± 57 pg/mL                                                                                                                                                                                            

  IL-6                                    427± 168 pg/mL                                                                                                                                                                                            

                                                                                                                                                                                                                                                    

  \[[@B25]\]                              Hu-AD-MSC                           Spheroid---2 days      4.2 × 10^7^/Centr.                                  CM versus *α*MEM:hTGF-b1                                                                   14.33 ± 6.71 versus 2.49 ± 2.39 pg/mL

  hVEGF                                   1,015.17 ± 170.97 pg/mL versus ND                                                                                                                                                                         

  hPDGF-AA                                Both ND                                                                                                                                                                                                   

                                                                                                                                                                                                                                                    

  \[[@B6]\]                               Hu-AD-SC\                           Spheroid---2 days      10^5^/Centr.                                        VEGF                                                                                       14.4 ± 0.4 ng/mL
                                          In *α*MEM---FBS                                                                                                                                                                                           

  FGF2                                    13.2 ± 2.2 ng/mL                                                                                                                                                                                          

  HGF                                     13.3 ± 2.3 ng/mL                                                                                                                                                                                          

  CXCL12                                  16.6 ± 2.9 ng/mL                                                                                                                                                                                          

  In CRM-hu allo                          No diff \>\< *α*MEM-FBS                                                                                                                                                                                   

  In CRM-serum (−)                        GF \<                                                                                                                                                                                                     

  In *α*MEM---FBS                         Monolayer---2 days                  10^5^/Centr.           GF\<\<\<                                                                                                                                       

                                          In CRM-hu allo                                                                                                                                                                                             GF\<\<\<

                                                                                                                                                                                                                                                    

  \[[@B5]\]                               Hu-AD-SC                            Monolayer---\          4 × 10^5^/Conc.                                     Spot density array hypox versus nomoxia                                                    
                                                                              72 hours                                                                                                                                                              

  GCSF                                    14.07 ± 3.84 versus 10.13 ± 4.21                                                                                                                                                                          

  GM-CSF                                  13.53 ± 1.26 versus 10.21 ± 1.44                                                                                                                                                                          

  IGFBP-1                                 9.48 ± 0.44 versus 5.56 ± 0.44                                                                                                                                                                            

  IGFBP-2                                 8.91 ± 0.02 versus 6.73 ± 0.31                                                                                                                                                                            

  IGF-II                                  10.62 ± 0.85 versus 4.61 ± 0.93                                                                                                                                                                           

  M-CSF                                   14.06 ± 0.13 versus 7.46 ± 1.69                                                                                                                                                                           

  M-CSF R                                 9.09 ± 0.20 versus 3.31 ± 1.75                                                                                                                                                                            

  PDGF R*β*                               17.67 ± 1.32 versus 11.47 ± 1.40                                                                                                                                                                          

  PDGF-AA                                 16.63 ± 1.33 versus 12.14 ± 2.12                                                                                                                                                                          

  VEGF                                    13.47 ± 1.26 versus 5.59 ± 1.22                                                                                                                                                                           

  EGF                                     11.06 ± 2.45 versus 34.14 ± 6.75                                                                                                                                                                          

                                                                                                                                                                                                                                                    

  \[[@B37]\]                              \(i\) AD-SC\                        NA                     NA                                                  AD-SC                                                                                      
                                          (ii) Hu dermal fibroblast                                                                                                                                                                                 

  VEGF                                    810.65 ± 56.92 pg/*μ*g DNA                                                                                                                                                                                

  IGF-I                                   328.33 ± 22.7 pg/*μ*g DNA                                                                                                                                                                                 

  Hu dermal fibroblast                                                                                                                                                                                                                              

  VEGF                                    28.4 ± 2.25 pg/*μ*g DNA                                                                                                                                                                                   

  IGFI                                    Undetectable                                                                                                                                                                                              

                                                                                                                                                                                                                                                    

  \[[@B34]\]                              Hu-MSC (Lonza)                      Monolayer---48 hours   70%/(---)                                           IGF-1                                                                                      1515.6 ± 211.8 pg/mL

  VEGF                                    465.8 ± 108.8 pg/mL                                                                                                                                                                                       

  TGF-b1                                  339.8 ± 14.4 pg/mL                                                                                                                                                                                        

  HGF                                     20.3 ± 7.9 pg/mL,                                                                                                                                                                                         

  FGF-2, PDGFBB, BMP-2, and SDF-1 (---)                                                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRM: clinically relevant med, hu allo: human allogenic serum, MP: microparticle, ND: not detected, SDF-1: stromal derived factor-1, PlGF: placental GF, bFGF: basic FGF, HGF: hepatocyte GF, PAC: peripheral blood angiogenic cells (from PB MN cells-floating), cPAC: healthy control PAC, ESC-EC: ESC derived endothelial cell, MCP-1: monocyte chemotactic protein-1, PDEGF: platelet derived endothelial cell GF, UPA: urokinase plasminogen activator, HEGF: heparin binding epidermal GF, TIMP-1: tissue inhibitor of metalloproteinase-1, IGFBP: insulin-like GF binding protein, IP-10: interferon inducible protein-1, ADM: adrenomedullin, DKK-1: Dickkopf-1, norm: normoxic, hypox = hypoxic, fg = fentogram.

###### 

Cell number to produce CM per application, volume, and mode of delivery of various cell sources for various conditions and the outcome.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference number                       Condition/disease                               Species                               Cell source of CM                     Culture medium/culture type---condition                  Cell number/application   Volume and mode of delivery                         Outcome
  -------------------------------------- ----------------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------------------------- ------------------------- --------------------------------------------------- --------------------
  \[[@B6]\]                              Hind limb ischemia---direct                     Female athymic mice---20--25 gr       Hu-AD-SC                              *α*MEM---FBS 10%/monolayer---hypox 1%                    12.000                    40 *μ*L---IM---7x                                   Good result

  CRM---Hu allo10%/spheroid---hypox 1%   48.000                                          Better result                                                                                                                                                                                                      

  *α*MEM---FBS 10%/spheroid---hypox 1%   Better result                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                            

  \[[@B9]\]                              Hind limb ischemia---10 days                    Male NOD-SCID mice---10--12 weeks     Hu-AF-SC--Ckit (+)                    *α*MEM---(−)/monolayer---normoxia                        500.000                   80 *μ*L---IM---4x                                   Good result

                                                                                                                                                                                                                                                                                                            

  \[[@B11]\]                             Full thickness wound---5 mm direct              Diabetic-immunodef. mice---17--23 g   Hu-UCB-CD34-EPC                       M199 basal medium (−)/monolayer---normoxia               1 × 10^6^                 100 *μ*L---intradermal injection                    Good result

                                                                                                                                                                                                                                                                                                            

  \[[@B14]\]                             Wound\                                          Male NOD-SCID mice---4-5weeks         Hu-BM-MSC                             *α*MEM---10% FBS/monolayer---normoxia                    1 × 10^8^                 100 *μ*L---SC---periphery wound                     Good result
                                         30--50 mm^2^; 120--140 mm^2^---48 hours                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                            

  \[[@B18]\]                             MCI 48 hours                                    Nude-athymic rat---6--8 weeks         Hu-BM-MNC-stro-3-MPC                  *α*MEM---(−)/monolayer---normoxia                        1 × 10^6^                 250 *μ*L Intramyocardial                            Good result

                                                                                                                                                                                                                                                                                                            

  \[[@B21]\]                             CCl4 injured acute hepatic failure---24 hours   SCID-NOD mice---6--8 weeks            Hu-AF-MSC                             DMEM---0.5% FBS/monolayer---normoxia                     1.5 × 10^6^               200 *μ*L---intrahepatic (left liver lobe)           Good result

  Hu-AF-MSC- HPL                         Better result                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                            

  \[[@B22]\]                             Fulminant hepatic failure---24 hours            Male SD rat---250--300 g              Hu-MSC                                DMEM---0.05% bovine serum albumin/monolayer---normoxia   1.5 × 10^6^               900 *μ*L penile vein                                Good result\
                                                                                                                                                                                                                                                                                                            Increased survival

  \[[@B23]\]                             Male SD rat---280--370 g                        Hu-BM-MSC                             NA---0.05% BSA/monolayer---normoxia   2 × 10^6^                                                900 *μ*L CM\              Good result\                                        
                                                                                                                                                                                                                              Penile vein               Increased survival                                  

                                                                                                                                                                                                                                                                                                            

  \[[@B24]\]                             Focal cerebral ischemia---72 hours              Male SD rat---350--400 g              Hu-EDT-SC                             DMEM (−)/monolayer---normoxia                            400.000                   10x10 *µ*L---intranasal (left-right)\               Good result
                                                                                                                                                                                                                                                        Every day D3-D15                                    

  BM-MSC (Lonza)                         Good result                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                            

  \[[@B25]\]                             Ischemic\                                       Male SD mouse---8 weeks               Hu-AD-MSC                             *α*MEM---(−)/spheroid---hypoxia 1%                       50.400                    Infusion 0.5 *µ*L/hour-7 days---lateral ventricle   Good result
                                         Stroke---8 days                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCID: severe combined immunodeficiency, NOD: nonobese diabetic, SD: Sprague-Dawley, Hu: human, AD: adipose tissue, SC: stem cell, AF: amniotic fluid, UCB: umbilical cord blood, EPC: endothelial progenitor cell, BM: bone marrow, MSC: mesenchymal SC, MNC: mononuclear cell, MPC: mesenchymal progenitor cell, HPL: hepatic progenitor-like cell, and EDT: exfoliated deciduous tooth.

[^1]: Academic Editor: Antonio Salgado
